These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 14517714)

  • 21. Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women.
    Salmen T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Pallonen H; Saarikoski S; Honkanen R; Mäenpää PH
    Ann Med; 2003; 35(4):282-8. PubMed ID: 12846271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I; Vignau J; Collier F; Cortet B
    Calcif Tissue Int; 2008 Nov; 83(5):315-23. PubMed ID: 18836675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The synergistic effect of sex hormone-binding globulin and aromatase genes on polycystic ovary syndrome phenotype.
    Xita N; Georgiou I; Lazaros L; Psofaki V; Kolios G; Tsatsoulis A
    Eur J Endocrinol; 2008 Jun; 158(6):861-5. PubMed ID: 18505907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study.
    Abrahamsen B; Bonnevie-Nielsen V; Ebbesen EN; Gram J; Beck-Nielsen H
    J Bone Miner Res; 2000 Aug; 15(8):1545-54. PubMed ID: 10934653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No association between hip geometry and four common polymorphisms associated with fracture: the Danish osteoporosis prevention study.
    Nissen N; Madsen JS; Bladbjerg EM; Beck Jensen JE; Jørgensen NR; Langdahl B; Abrahamsen B; Brixen K
    Calcif Tissue Int; 2009 Apr; 84(4):276-85. PubMed ID: 19225709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women.
    Kim JG; Choi YM; Moon SY; Lee JY
    Menopause; 2003; 10(6):544-9. PubMed ID: 14627864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?
    Silvestri S; Thomsen AB; Gozzini A; Bagger Y; Christiansen C; Brandi ML
    Menopause; 2006; 13(3):451-61. PubMed ID: 16735942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women.
    Scariano JK; Simplicio SG; Montoya GD; Garry PJ; Baumgartner RN
    Calcif Tissue Int; 2004 Jun; 74(6):501-8. PubMed ID: 15354857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale population-based study shows no association between common polymorphisms of the TGFB1 gene and BMD in women.
    McGuigan FE; Macdonald HM; Bassiti A; Farmer R; Bear S; Stewart A; Black A; Fraser WD; Welsh F; Reid DM; Ralston SH
    J Bone Miner Res; 2007 Feb; 22(2):195-202. PubMed ID: 17059371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study.
    Haiman CA; Brown M; Hankinson SE; Spiegelman D; Colditz GA; Willett WC; Kantoff PW; Hunter DJ
    Cancer Res; 2002 Feb; 62(4):1045-9. PubMed ID: 11861380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic markers, bone mineral density, and serum osteocalcin levels.
    Sowers M; Willing M; Burns T; Deschenes S; Hollis B; Crutchfield M; Jannausch M
    J Bone Miner Res; 1999 Aug; 14(8):1411-9. PubMed ID: 10457274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women.
    Baghaei F; Rosmond R; Westberg L; Hellstrand M; Eriksson E; Holm G; Björntorp P
    Obes Res; 2003 Apr; 11(4):578-85. PubMed ID: 12690088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein E gene polymorphism and bone loss: estrogen status modifies the influence of apolipoprotein E on bone loss.
    Salamone LM; Cauley JA; Zmuda J; Pasagian-Macaulay A; Epstein RS; Ferrell RE; Black DM; Kuller LH
    J Bone Miner Res; 2000 Feb; 15(2):308-14. PubMed ID: 10703933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of estrogen receptor beta gene polymorphisms with spinal bone mineral density in peri- and post-menopausal Greek women.
    Efstathiadou Z; Koukoulis G; Stakias N; Challa A; Zintzaras E; Tsatsoulis A
    Maturitas; 2006 Mar; 53(4):380-5. PubMed ID: 16125346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
    Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
    Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
    Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
    Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women.
    Heikkinen AM; Niskanen LK; Salmi JA; Koulu M; Pesonen U; Uusitupa MI; Komulainen MH; Tuppurainen MT; Kröger H; Jurvelin J; Saarikoski S
    Bone; 2004 Sep; 35(3):589-94. PubMed ID: 15336593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.